A brief review on molecular, genetic and imaging techniques for HCV fibrosis evaluation

Virology Journal

Volumn 8, Issue , 2011, Pages

  Ahmad, Waqar ^a   Ijaz, Bushra ^a   Gull, Sana ^a   Asad, Sultan ^a   Khaliq, Saba ^a   Jahan, Shah ^a   Sarwar, Muhammad T ^a   Kausar, Humera ^a   Sumrin, Aleena ^a   Shahid, Imran ^a   Hassan, Sajida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA 2 MACROGLOBULIN; APOLIPOPROTEIN A1; ASPARTATE AMINOTRANSFERASE; BIOLOGICAL MARKER; COLLAGEN TYPE 4; CYTOCHROME P450 2C8; GAMMA GLUTAMYLTRANSFERASE; HERMES ANTIGEN; HYALURONIC ACID; INTERCELLULAR ADHESION MOLECULE 1; MATRIX METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR; TISSUE INHIBITOR OF METALLOPROTEINASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR ALPHA;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIFFUSION WEIGHTED IMAGING; ECHOGRAPHY; GENETIC MARKER; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; NON INVASIVE PROCEDURE; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROTEIN EXPRESSION; PROTHROMBIN TIME; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; THROMBOCYTE COUNT; ANIMAL; DIAGNOSTIC IMAGING; EVALUATION; GENETICS; METHODOLOGY; PATHOLOGY; VIROLOGY;

HEPATITIS C VIRUS; NUCLEOPOLYHEDROVIRUS;

ANIMALS; DIAGNOSTIC IMAGING; GENETIC MARKERS; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS;

EID: 79551688230     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-53     Document Type: Review

References (181)

1. Memon MI, Memon MA: Hepatitis C: an epidemiological review. J Viral Hepat 2002, 9:84-100. (Pubitemid 36002471)
2. WHO: Global distribution of hepatitis A, B and C, 2001. Weakly Epidimiological Records 2002, 77, 41,48.
3. Marcellin P, Asselah T, Boyer N: Fibrosis and disease progression in hepatitis C. Hepatology 2002, 36:S47-56.
4. Afdhal NH, Nunes D: Evaluation of liver fibrosis: a concise review. Am J Gastroenterol 2004, 99:1160-1174. (Pubitemid 38917824)
5. Dienstag JL, McHutchison JG: American Gastroenterological Association technical review on the management of hepatitis C. Gastroenterology 2006, 130:231-264, quiz 214-237.
6. Clark JM: The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol 2006, 40(Suppl 1):S5-10.
7. Harbin WP, Robert NJ, Ferrucci JT Jr: Diagnosis of cirrhosis based on regional changes in hepatic morphology: a radiological and pathological analysis. Radiology 1980, 135:273-283. (Pubitemid 10105887)
8. Gressner AM: The cell biology of liver fibrogenesis - an imbalance of proliferation, growth arrest and apoptosis of myofibroblasts. Cell Tissue Res 1998, 292:447-452.
9. Arthur MJ: Reversibility of liver fibrosis and cirrhosis following treatment for hepatitis C. Gastroenterology 2002, 122:1525-1528.
10. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G: Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001, 33:1358-1364. (Pubitemid 32496971)
11. El-Serag HB: Hepatocellular carcinoma and hepatitis C in the United States. Hepatology 2002, 36:S74-83.
12. Parkes J, Guha IN, Roderick P, Rosenberg W: Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006, 44:462-474. (Pubitemid 43227870)
13. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, de Ledinghen V, Marcellin P, Dhumeaux D, Trinchet JC, Beaugrand M: Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 2005, 41:48-54. (Pubitemid 40066382)
14. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K: The role of liver biopsy in chronic hepatitis C. Hepatology 2001, 33:196-200. (Pubitemid 32016902)
15. Booth JC, O'Grady J, Neuberger J: Clinical guidelines on the management of hepatitis C. Gut 2001, 49(Suppl 1):I1-21.
16. Knodell RG, Ishak KG, Black WC, Chen TS, Craig R, Kaplowitz N, Kiernan TW, Wollman J: Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology 1981, 1:431-435. (Pubitemid 12218164)
17. group TFMcs: Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994, 20:15-20.
18. Ishak K, Baptista A, Bianchi L, Callea F, De Groote J, Gudat F, Denk H, Desmet V, Korb G, MacSween RN, et al: Histological grading and staging of chronic hepatitis. J Hepatol 1995, 22:696-699.
19. Goldin RD, Goldin JG, Burt AD, Dhillon PA, Hubscher S, Wyatt J, Patel N: Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol 1996, 25:649-654. (Pubitemid 26373881)
20. Westin J, Lagging LM, Wejstal R, Norkrans G, Dhillon AP: Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver 1999, 19:183-187. (Pubitemid 29261583)
21. Friedman SL: Molecular regulation of hepatic fibrosis, an integrated cellular response to tissue injury. J Biol Chem 2000, 275:2247-2250.
22. Friedman SL: Liver fibrosis - from bench to bedside. J Hepatol 2003, 38(Suppl 1):S38-53.
23. Kelleher TB, Afdhal N: Noninvasive assessment of liver fibrosis. Clin Liver Dis 2005, 9:667-683, vii.
24. Idobe Y, Murawaki Y, Ikuta Y, Koda M, Kawasaki H: Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med 1998, 37:568-575. (Pubitemid 128519095)
25. Saif MW, Alexander D, Wicox CM: Serum Alkaline Phosphatase Level as a Prognostic Tool in Colorectal Cancer: A Study of 105 patients. J Appl Res 2005, 5:88-95.
26. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T: Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet 2001, 357:1069-1075. (Pubitemid 32322537)
27. Forns X, Ampurdanes S, Llovet JM, Aponte J, Quinto L, Martinez-Bauer E, Bruguera M, Sanchez-Tapias JM, Rodes J: Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology 2002, 36:986-992.
28. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS: A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003, 38:518-526. (Pubitemid 36919874)
29. Thabut D, Simon M, Myers RP, Messous D, Thibault V, Imbert-Bismut F, Poynard T: Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003, 37:1220-1221, author reply 1221.
30. Guechot J, Loria A, Serfaty L, Giral P, Giboudeau J, Poupon R: Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: effect of alpha-interferon therapy. J Hepatol 1995, 22:22-26.
31. Pares A, Deulofeu R, Gimenez A, Caballeria L, Bruguera M, Caballeria J, Ballesta AM, Rodes J: Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996, 24:1399-1403. (Pubitemid 26399038)
32. McHutchison JG, Blatt LM, de Medina M, Craig JR, Conrad A, Schiff ER, Tong MJ: Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000, 15:945-951.
33. Hayasaka A, Saisho H: Serum markers as tools to monitor liver fibrosis. Digestion 1998, 59:381-384. (Pubitemid 28360697)
34. Guechot J, Laudat A, Loria A, Serfaty L, Poupon R, Giboudeau J: Diagnostic accuracy of hyaluronan and type III procollagen aminoterminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996, 42:558-563. (Pubitemid 26111874)
35. Fabris C, Falleti E, Federico E, Toniutto P, Pirisi M: A comparison of four serum markers of fibrosis in the diagnosis of cirrhosis. Ann Clin Biochem 1997, 34(Pt 2):151-155. (Pubitemid 27121035)
36. George DK, Ramm GA, Walker NI, Powell LW, Crawford DH: Elevated serum type IV collagen: a sensitive indicator of the presence of cirrhosis in haemochromatosis. J Hepatol 1999, 31:47-52. (Pubitemid 29287608)
37. Murawaki Y, Ikuta Y, Koda M, Yamada S, Kawasaki H: Comparison of serum 7 S fragment of type IV collagen and serum central triple-helix of type IV collagen for assessment of liver fibrosis in patients with chronic viral liver disease. J Hepatol 1996, 24:148-154. (Pubitemid 26057951)
38. Boeker KH, Haberkorn CI, Michels D, Flemming P, Manns MP, Lichtinghagen R: Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis C. Clin Chim Acta 2002, 316:71-81. (Pubitemid 34028190)
39. Zhang BB, Cai WM, Weng HL, Hu ZR, Lu J, Zheng M, Liu RH: Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis. World J Gastroenterol 2003, 9:2490-2496. (Pubitemid 37461254)
40. Johansen JS, Christoffersen P, Moller S, Price PA, Henriksen JH, Garbarsch C, Bendtsen F: Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000, 32:911-920. (Pubitemid 30368084)
41. Kanzler S, Baumann M, Schirmacher P, Dries V, Bayer E, Gerken G, Dienes HP, Lohse AW: Prediction of progressive liver fibrosis in hepatitis C infection by serum and tissue levels of transforming growth factor-beta. J Viral Hepat 2001, 8:430-437. (Pubitemid 35013568)
42. Patel K, Gordon SC, Jacobson I, Hezode C, Oh E, Smith KM, Pawlotsky JM, McHutchison JG: Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004, 41:935-942. (Pubitemid 39575660)
43. Zaman A, Rosen HR, Ingram K, Corless CL, Oh E, Smith K: Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007, 120:280, e289-214.
44. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, Hubscher S, Roskams T, Pinzani M, Arthur MJ: Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology 2004, 127:1704-1713. (Pubitemid 39575849)
45. Leroy V, Monier F, Bottari S, Trocme C, Sturm N, Hilleret MN, Morel F, Zarski JP: Circulating matrix metalloproteinases 1, 2, 9 and their inhibitors TIMP-1 and TIMP-2 as serum markers of liver fibrosis in patients with chronic hepatitis C: comparison with PIIINP and hyaluronic acid. Am J Gastroenterol 2004, 99:271-279.
46. Murawaki Y, Ikuta Y, Nishimura Y, Koda M, Kawasaki H: Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: a comparative analysis. J Hepatol 1995, 23:145-152.
47. Murawaki Y, Ikuta Y, Okamoto K, Koda M, Kawasaki H: Diagnostic value of serum markers of connective tissue turnover for predicting histological staging and grading in patients with chronic hepatitis C. J Gastroenterol 2001, 36:399-406. (Pubitemid 32633448)
48. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K: Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with nonalcoholic fatty liver disease. Liver Int 2005, 25:779-786. (Pubitemid 41038659)
49. Halfon P, Bourliere M, Penaranda G, Deydier R, Renou C, Botta-Fridlund D, Tran A, Portal I, Allemand I, Rosenthal-Allieri A, Ouzan D: Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005, 4:6.
50. Hakala BE, White C, Recklies AD: Human cartilage gp-39, a major secretory product of articular chondrocytes and synovial cells, is a mammalian member of a chitinase protein family. J Biol Chem 1993, 268:25803-25810. (Pubitemid 23358198)
51. Saitou Y, Shiraki K, Yamanaka Y, Yamaguchi Y, Kawakita T, Yamamoto N, Sugimoto K, Murata K, Nakano T: Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005, 11:476-481. (Pubitemid 40185578)
52. Sanvisens A, Serra I, Tural C, Tor J, Ojanguren I, Barluenga E, Rey-Joly C, Clotet B, Muga R: Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat 2009, 16:513-518.
53. Schiavon LL, Carvalho-Filho RJ, Narciso-Schiavon JL, Medina-Pestana JO, Lanzoni VP, Ferraz ML, Silva AE: YKL-40 and hyaluronic acid (HA) as noninvasive markers of liver fibrosis in kidney transplant patients with HCV chronic infection. Scand J Gastroenterol 2010, 45:615-622.
54. Felig P: The glucose-alanine cycle. Metabolism 1973, 22:179-207.
55. Daxboeck F, Gattringer R, Mustafa S, Bauer C, Assadian O: Elevated serum alanine aminotransferase (ALT) levels in patients with serologically verified Mycoplasma pneumoniae pneumonia. Clin Microbiol Infect 2005, 11:507-510. (Pubitemid 40744402)
56. Sherman KE: Alanine aminotransferase in clinical practice. A review. Arch Intern Med 1991, 151:260-265.
57. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB: Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests. Clin Chem 2000, 46:2027-2049.
58. Akkaya O, Kiyici M, Yilmaz Y, Ulukaya E, Yerci O: Clinical significance of activity of ALT enzyme in patients with hepatitis C virus. World J Gastroenterol 2007, 13:5481-5485. (Pubitemid 47610993)
59. Kim HJ, Oh SW, Kim DJ, Choi EY: Abundance of immunologically active alanine aminotransferase in sera of liver cirrhosis and hepatocellular carcinoma patients. Clin Chem 2009, 55:1022-1025.
60. Shiffman ML, Diago M, Tran A, Pockros P, Reindollar R, Prati D, Rodriguez-Torres M, Lardelli P, Blotner S, Zeuzem S: Chronic hepatitis C in patients with persistently normal alanine transaminase levels. Clin Gastroenterol Hepatol 2006, 4:645-652.
61. Okuda M, Li K, Beard MR, Showalter LA, Scholle F, Lemon SM, Weinman SA: Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology 2002, 122:366-375. (Pubitemid 34116988)
62. Zechini B, Pasquazzi C, Aceti A: Correlation of serum aminotransferases with HCV RNA levels and histological findings in patients with chronic hepatitis C: the role of serum aspartate transaminase in the evaluation of disease progression. Eur J Gastroenterol Hepatol 2004, 16:891-896. (Pubitemid 39179659)
63. Cedrone A, Covino M, Caturelli E, Pompili M, Lorenzelli G, Villani MR, Valle D, Sperandeo M, Rapaccini GL, Gasbarrini G: Utility of alpha-fetoprotein (AFP) in the screening of patients with virus-related chronic liver disease: does different viral etiology influence AFP levels in HCC? A study in 350 western patients. Hepatogastroenterology 2000, 47:1654-1658.
64. Chu CW, Hwang SJ, Luo JC, Lai CR, Tsay SH, Li CP, Wu JC, Chang FY, Lee SD: Clinical, virologic, and pathologic significance of elevated serum alpha-fetoprotein levels in patients with chronic hepatitis C. J Clin Gastroenterol 2001, 32:240-244.
65. Chen TM, Huang PT, Tsai MH, Lin LF, Liu CC, Ho KS, Siauw CP, Chao PL, Tung JN: Predictors of alpha-fetoprotein elevation in patients with chronic hepatitis C, but not hepatocellular carcinoma, and its normalization after pegylated interferon alfa 2a-ribavirin combination therapy. J Gastroenterol Hepatol 2007, 22:669-675.
66. Tamura Y, Yamagiwa S, Aoki Y, Kurita S, Suda T, Ohkoshi S, Nomoto M, Aoyagi Y: Serum alpha-fetoprotein levels during and after interferon therapy and the development of hepatocellular carcinoma in patients with chronic hepatitis C. Dig Dis Sci 2009, 54:2530-2537.
67. Aster RH: Pooling of platelets in the spleen: role in the pathogenesis of "hypersplenic" thrombocytopenia. J Clin Invest 1966, 45:645-657.
68. Kawasaki T, Takeshita A, Souda K, Kobayashi Y, Kikuyama M, Suzuki F, Kageyama F, Sasada Y, Shimizu E, Murohisa G, et al: Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. Am J Gastroenterol 1999, 94:1918-1922. (Pubitemid 29315911)
69. Adinolfi LE, Giordano MG, Andreana A, Tripodi MF, Utili R, Cesaro G, Ragone E, Durante Mangoni E, Ruggiero G: Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 2001, 113:590-595. (Pubitemid 32524375)
70. Lackner C, Struber G, Liegl B, Leibl S, Ofner P, Bankuti C, Bauer B, Stauber RE: Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41:1376-1382. (Pubitemid 40770291)
71. Croquet V, Vuillemin E, Ternisien C, Pilette C, Oberti F, Gallois Y, Trossaert M, Rousselet MC, Chappard D, Cales P: Prothrombin index is an indirect marker of severe liver fibrosis. Eur J Gastroenterol Hepatol 2002, 14:1133-1141. (Pubitemid 35178775)
72. Pilette C, Oberti F, Aube C, Rousselet MC, Bedossa P, Gallois Y, Rifflet H, Cales P: Non-invasive diagnosis of esophageal varices in chronic liver diseases. J Hepatol 1999, 31:867-873. (Pubitemid 29514220)
73. Craxi A, Camma C, Giunta M: Clinical aspects of bleeding complications in cirrhotic patients. Blood Coagul Fibrinolysis 2000, 11(Suppl 1):S75-79.
74. Sheth SG, Flamm SL, Gordon FD, Chopra S: AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44-48. (Pubitemid 29065511)
75. Reedy DW, Loo AT, Levine RA: AST/ALT ratio > or = 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 1998, 43:2156-2159.
76. Giannini E, Risso D, Botta F, Chiarbonello B, Fasoli A, Malfatti F, Romagnoli P, Testa E, Ceppa P, Testa R: Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003, 163:218-224. (Pubitemid 36120190)
77. Fujii H, Enomoto M, Fukushima W, Ohfuji S, Mori M, Kobayashi S, Iwai S, Morikawa H, Tamori A, Sakaguchi H, et al: Noninvasive laboratory tests proposed for predicting cirrhosis in patients with chronic hepatitis C are also useful in patients with non-alcoholic steatohepatitis. J Gastroenterol 2009, 44:608-614.
78. Poynard T, Morra R, Halfon P, Castera L, Ratziu V, Imbert-Bismut F, Naveau S, Thabut D, Lebrec D, Zoulim F, et al: Meta-analyses of FibroTest diagnostic value in chronic liver disease. BMC Gastroenterol 2007, 7:40.
79. Cales P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F: A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005, 42:1373-1381. (Pubitemid 43260040)
80. Bourliere M, Penaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, Lecomte L, Castellani P, Rosenthal-Allieri MA, Gerolami R, et al: Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J Viral Hepat 2006, 13:659-670. (Pubitemid 44401194)
81. Parise ER, Oliveira AC, Figueiredo-Mendes C, Lanzoni V, Martins J, Nader H, Ferraz ML: Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006, 26:1095-1099. (Pubitemid 44548838)
82. de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, Dhumeaux D, Beaugrand M: Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006, 41:175-179.
83. Halfon P, Bacq Y, De Muret A, Penaranda G, Bourliere M, Ouzan D, Tran A, Botta D, Renou C, Brechot MC, et al: Comparison of test performance profile for blood tests of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:395-402. (Pubitemid 46201720)
84. Leroy V, Halfon P, Bacq Y, Boursier J, Rousselet MC, Bourliere M, de Muret A, Sturm N, Hunault G, Penaranda G, et al: Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data. Clin Biochem 2008, 41:1368-1376.
85. Cales P, de Ledinghen V, Halfon P, Bacq Y, Leroy V, Boursier J, Foucher J, Bourliere M, de Muret A, Sturm N, et al: Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008, 28:1352-1362.
86. Kamphues C, Lotz K, Rocken C, Berg T, Eurich D, Pratschke J, Neuhaus P, Neumann UP: Chances and limitations of non-invasive tests in the assessment of liver fibrosis in liver transplant patients. Clin Transplant 2010, 24:652-659.
87. Teare JP, Sherman D, Greenfield SM, Simpson J, Bray G, Catterall AP, Murray-Lyon IM, Peters TJ, Williams R, Thompson RP: Comparison of serum procollagen III peptide concentrations and PGA index for assessment of hepatic fibrosis. Lancet 1993, 342:895-898. (Pubitemid 23291593)
88. Naveau S, Poynard T, Benattar C, Bedossa P, Chaput JC: Alpha-2- macroglobulin and hepatic fibrosis. Diagnostic interest. Dig Dis Sci 1994, 39:2426-2432.
89. Oberti F, Valsesia E, Pilette C, Rousselet MC, Bedossa P, Aube C, Gallois Y, Rifflet H, Maiga MY, Penneau-Fontbonne D, Cales P: Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997, 113:1609-1616. (Pubitemid 27461247)
90. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J: Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology 2003, 38:481-492. (Pubitemid 36919870)
91. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V: Prospective analysis of discordant results between biochemical markers and biopsy in patients with chronic hepatitis C. Clin Chem 2004, 50:1344-1355. (Pubitemid 38970641)
92. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut D, Munteanu M, et al: Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease. Clin Gastroenterol Hepatol 2005, 3:167-174. (Pubitemid 40220312)
93. Sebastiani G, Alberti A: Non invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol 2006, 12:3682-3694. (Pubitemid 43950946)
94. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C: Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010, 10:103.
95. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, et al: A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease. Comp Hepatol 2002, 1:3.
96. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F: Biochemical markers of liver fibrosis in patients infected by hepatitis C virus: longitudinal validation in a randomized trial. J Viral Hepat 2002, 9:128-133. (Pubitemid 36002476)
97. Rossi E, Adams L, Prins A, Bulsara M, de Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G: Validation of the FibroTest biochemical markers score in assessing liver fibrosis in hepatitis C patients. Clin Chem 2003, 49:450-454. (Pubitemid 36250205)
98. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P, Thibault V, Benhamou Y, Moussalli J, et al: A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006, 52:1887-1896. (Pubitemid 44470696)
99. Halfon P, Bourliere M, Deydier R, Botta-Fridlund D, Renou C, Tran A, Portal I, Allemand I, Bertrand JJ, Rosenthal-Allieri A, et al: Independent prospective multicenter validation of biochemical markers (fibrotest-actitest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C: the fibropaca study. Am J Gastroenterol 2006, 101:547-555. (Pubitemid 43340931)
100. Halfon P, Munteanu M, Poynard T: FibroTest-ActiTest as a non-invasive marker of liver fibrosis. Gastroenterol Clin Biol 2008, 32:22-39.
101. Myers RP, De Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T: Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count, and age-platelet index. Dig Dis Sci 2003, 48:146-153. (Pubitemid 36232774)
102. Bedossa P, Dargere D, Paradis V: Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457. (Pubitemid 37466971)
103. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M: Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology 2005, 42:838-845. (Pubitemid 41401121)
104. Shaheen AA, Myers RP: Systematic review and meta-analysis of the diagnostic accuracy of fibrosis marker panels in patients with HIV/hepatitis C coinfection. HIV Clin Trials 2008, 9:43-51. (Pubitemid 351214240)
105. Cales P, Boursier J, Bertrais S, Oberti F, Gallois Y, Fouchard-Hubert I, Dib N, Zarski JP, Rousselet MC: Optimization and robustness of blood tests for liver fibrosis and cirrhosis. Clin Biochem 2010, 43:1315-1322.
106. Koda M, Matunaga Y, Kawakami M, Kishimoto Y, Suou T, Murawaki Y: FibroIndex, a practical index for predicting significant fibrosis in patients with chronic hepatitis C. Hepatology 2007, 45:297-306. (Pubitemid 46374586)
107. Lee MH, Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Yang JM, Han KH, Cho SW: Comparison of surrogate serum markers and transient elastography (Fibroscan) for assessing cirrhosis in patients with chronic viral hepatitis. Dig Dis Sci 2010, 55:3552-3560.
108. El-Shabrawi MH, Mohsen NA, Sherif MM, El-Karaksy HM, Abou-Yosef H, El-Sayed HM, Riad H, Bahaa N, Isa M, El-Hennawy A: Noninvasive assessment of hepatic fibrosis and necroinflammatory activity in Egyptian children with chronic hepatitis C virus infection using FibroTest and ActiTest. Eur J Gastroenterol Hepatol 2010, 22:946-951.
109. Poynard T, Ratziu V, Naveau S, Thabut D, Charlotte F, Messous D, Capron D, Abella A, Massard J, Ngo Y, et al: The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis. Comp Hepatol 2005, 4:10.
110. Lok AS, Ghany MG, Goodman ZD, Wright EC, Everson GT, Sterling RK, Everhart JE, Lindsay KL, Bonkovsky HL, Di Bisceglie AM, et al: Predicting cirrhosis in patients with hepatitis C based on standard laboratory tests: results of the HALT-C cohort. Hepatology 2005, 42:282-292. (Pubitemid 41061080)
111. Cheong JY, Um SH, Seo YS, Kim DJ, Hwang SG, Lee YJ, Cho M, Yang JM, Kim YB, Park YN, Cho SW: Non-Invasive Index for Predicting Significant Liver Fibrosis: Comparison of Diagnostic Performances in Patients with Chronic Hepatitis B and C. Dig Dis Sci 2010, 56:555-563.
112. Islam S, Antonsson L, Westin J, Lagging M: Cirrhosis in hepatitis C virus-infected patients can be excluded using an index of standard biochemical serum markers. Scand J Gastroenterol 2005, 40:867-872. (Pubitemid 40978865)
113. Ohta T, Sakaguchi K, Fujiwara A, Fujioka S, Iwasaki Y, Makino Y, Araki Y, Shiratori Y: Simple surrogate index of the fibrosis stage in chronic hepatitis C patients using platelet count and serum albumin level. Acta Med Okayama 2006, 60:77-84. (Pubitemid 43763977)
114. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T: Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 2001, 96:3142-3146. (Pubitemid 33095354)
115. Cheung RC, Currie S, Shen H, Bini EJ, Ho SB, Anand BS, Hu KQ, Wright TL, Morgan TR: Can we predict the degree of fibrosis in chronic hepatitis C patients using routine blood tests in our daily practice? J Clin Gastroenterol 2008, 42:827-834.
116. Bonacini M, Hadi G, Govindarajan S, Lindsay KL: Utility of a discriminant score for diagnosing advanced fibrosis or cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1997, 92:1302-1304. (Pubitemid 27328588)
117. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, Kench J, Farrell G, McCaughan GW, Jeffrey GP: Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005, 51:1867-1873. (Pubitemid 41368177)
118. Leroy V, Hilleret MN, Sturm N, Trocme C, Renversez JC, Faure P, Morel F, Zarski JP: Prospective comparison of six non-invasive scores for the diagnosis of liver fibrosis in chronic hepatitis C. J Hepatol 2007, 46:775-782. (Pubitemid 46529041)
119. Becker L, Salameh W, Sferruzza A, Zhang K, ng Chen R, Malik R, Reitz R, Nasser I, Afdhal NH: Validation of hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009, 7:696-701.
120. Guechot J, Lasnier E, Sturm N, Paris A, Zarski JP: Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010, 411:86-91.
121. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, Moore RE, Afdhal NH: Prediction of hepatic fibrosis in HIV/HCV coinfected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005, 43:78-84. (Pubitemid 40805276)
122. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, M SS, Torriani FJ, Dieterich DT, Thomas DL, et al: Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006, 43:1317-1325. (Pubitemid 43980111)
123. Vallet-Pichard A, Mallet V, Nalpas B, Verkarre V, Nalpas A, Dhalluin-Venier V, Fontaine H, Pol S: FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007, 46:32-36. (Pubitemid 47171918)
124. Mallet V, Dhalluin-Venier V, Roussin C, Bourliere M, Pettinelli ME, Giry C, Vallet-Pichard A, Fontaine H, Pol S: The accuracy of the FIB-4 index for the diagnosis of mild fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2009, 29:409-415.
125. Sud A, Hui JM, Farrell GC, Bandara P, Kench JG, Fung C, Lin R, Samarasinghe D, Liddle C, McCaughan GW, George J: Improved prediction of fibrosis in chronic hepatitis C using measures of insulin resistance in a probability index. Hepatology 2004, 39:1239-1247. (Pubitemid 38569045)
126. Testa R, Testa E, Giannini E, Borro P, Milazzo S, Isola L, Ceppa P, Lantieri PB, Risso D: Noninvasive ratio indexes to evaluate fibrosis staging in chronic hepatitis C: role of platelet count/spleen diameter ratio index. J Intern Med 2006, 260:142-150. (Pubitemid 44051338)
127. Fortunato G, Castaldo G, Oriani G, Cerini R, Intrieri M, Molinaro E, Gentile I, Borgia G, Piazza M, Salvatore F, Sacchetti L: Multivariate discriminant function based on six biochemical markers in blood can predict the cirrhotic evolution of chronic hepatitis. Clin Chem 2001, 47:1696-1700. (Pubitemid 32781585)
128. Aube C, Oberti F, Korali N, Namour MA, Loisel D, Tanguy JY, Valsesia E, Pilette C, Rousselet MC, Bedossa P, et al: Ultrasonographic diagnosis of hepatic fibrosis or cirrhosis. J Hepatol 1999, 30:472-478. (Pubitemid 29113237)
129. Mathiesen UL, Franzen LE, Aselius H, Resjo M, Jacobsson L, Foberg U, Fryden A, Bodemar G: Increased liver echogenicity at ultrasound examination reflects degree of steatosis but not of fibrosis in asymptomatic patients with mild/moderate abnormalities of liver transaminases. Dig Liver Dis 2002, 34:516-522. (Pubitemid 34830694)
130. Colli A, Fraquelli M, Andreoletti M, Marino B, Zuccoli E, Conte D: Severe liver fibrosis or cirrhosis: accuracy of US for detection-analysis of 300 cases. Radiology 2003, 227:89-94. (Pubitemid 36384184)
131. Zheng RQ, Wang QH, Lu MD, Xie SB, Ren J, Su ZZ, Cai YK, Yao JL: Liver fibrosis in chronic viral hepatitis: an ultrasonographic study. World J Gastroenterol 2003, 9:2484-2489. (Pubitemid 37461253)
132. Colli A, Colucci A, Paggi S, Fraquelli M, Massironi S, Andreoletti M, Michela V, Conte D: Accuracy of a predictive model for severe hepatic fibrosis or cirrhosis in chronic hepatitis C. World J Gastroenterol 2005, 11:7318-7322. (Pubitemid 43137683)
133. Shen L, Li JQ, Zeng MD, Lu LG, Fan ST, Bao H: Correlation between ultrasonographic and pathologic diagnosis of liver fibrosis due to chronic virus hepatitis. World J Gastroenterol 2006, 12:1292-1295.
134. Sandrin L, Tanter M, Gennisson JL, Catheline S, Fink M: Shear elasticity probe for soft tissues with 1-D transient elastography. IEEE Trans Ultrason Ferroelectr Freq Control 2002, 49:436-446. (Pubitemid 34555341)
135. Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, et al: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003, 29:1705-1713. (Pubitemid 38091720)
136. Colloredo G, Guido M, Sonzogni A, Leandro G: Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol 2003, 39:239-244. (Pubitemid 36920560)
137. Cobbold JF, Morin S, Taylor-Robinson SD: Transient elastography for the assessment of chronic liver disease: ready for the clinic? World J Gastroenterol 2007, 13:4791-4797. (Pubitemid 47496742)
138. Kettaneh A, Marcellin P, Douvin C, Poupon R, Ziol M, Beaugrand M, de Ledinghen V: Features associated with success rate and performance of FibroScan measurements for the diagnosis of cirrhosis in HCV patients: a prospective study of 935 patients. J Hepatol 2007, 46:628-634. (Pubitemid 46420381)
139. Foucher J, Chanteloup E, Vergniol J, Castera L, Le Bail B, Adhoute X, Bertet J, Couzigou P, de Ledinghen V: Diagnosis of cirrhosis by transient elastography (FibroScan): a prospective study. Gut 2006, 55:403-408. (Pubitemid 43268281)
140. Maor Y, Halfon P, Bashari D, Penaranda G, Morali G, Klar R, Bar-Meir S, Martinowitz U, Oren R: Fibrotest or Fibroscan for evaluation of liver fibrosis in haemophilia patients infected with hepatitis C. Haemophilia 2010, 16:148-154.
141. Friedrich-Rust M, Ong MF, Herrmann E, Dries V, Samaras P, Zeuzem S, Sarrazin C: Real-time elastography for noninvasive assessment of liver fibrosis in chronic viral hepatitis. AJR Am J Roentgenol 2007, 188:758-764.
142. Fraquelli M, Rigamonti C, Casazza G, Conte D, Donato MF, Ronchi G, Colombo M: Reproducibility of transient elastography in the evaluation of liver fibrosis in patients with chronic liver disease. Gut 2007, 56:968-973. (Pubitemid 46999083)
143. Vizzutti F, Arena U, Romanelli RG, Rega L, Foschi M, Colagrande S, Petrarca A, Moscarella S, Belli G, Zignego AL, et al: Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007, 45:1290-1297. (Pubitemid 46775793)
144. de Ledinghen V, Vergniol J: Transient elastography for the diagnosis of liver fibrosis. Expert Rev Med Devices 2010, 7:811-823.
145. Corpechot C, El Naggar A, Poujol-Robert A, Ziol M, Wendum D, Chazouilleres O, de Ledinghen V, Dhumeaux D, Marcellin P, Beaugrand M, Poupon R: Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006, 43:1118-1124. (Pubitemid 43724636)
146. Ganne-Carrie N, Ziol M, de Ledinghen V, Douvin C, Marcellin P, Castera L, Dhumeaux D, Trinchet JC, Beaugrand M: Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases. Hepatology 2006, 44:1511-1517. (Pubitemid 44953656)
147. Shaheen AA, Wan AF, Myers RP: FibroTest and FibroScan for the prediction of hepatitis C-related fibrosis: a systematic review of diagnostic test accuracy. Am J Gastroenterol 2007, 102:2589-2600. (Pubitemid 47631778)
148. Friedrich-Rust M, Wunder K, Kriener S, Sotoudeh F, Richter S, Bojunga J, Herrmann E, Poynard T, Dietrich CF, Vermehren J, et al: Liver fibrosis in viral hepatitis: noninvasive assessment with acoustic radiation force impulse imaging versus transient elastography. Radiology 2009, 252:595-604.
149. Sanchez-Conde M, Montes-Ramirez ML, Miralles P, Alvarez JM, Bellon JM, Ramirez M, Arribas JR, Gutierrez I, Lopez JC, Cosin J, et al: Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. J Viral Hepat 2010, 17:280-286.
150. Abu-Yousef MM: Duplex Doppler sonography of the hepatic vein in tricuspid regurgitation. AJR Am J Roentgenol 1991, 156:79-83.
151. Albrecht T, Blomley MJ, Cosgrove DO, Taylor-Robinson SD, Jayaram V, Eckersley R, Urbank A, Butler-Barnes J, Patel N: Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999, 353:1579-1583. (Pubitemid 29219208)
152. Hirata M, Akbar SM, Horiike N, Onji M: Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur J Clin Invest 2001, 31:528-535. (Pubitemid 32579390)
153. Bonekamp S, Kamel I, Solga S, Clark J: Can imaging modalities diagnose and stage hepatic fibrosis and cirrhosis accurately? J Hepatol 2009, 50:17-35.
154. Lucidarme O, Baleston F, Cadi M, Bellin MF, Charlotte F, Ratziu V, Grenier PA: Non-invasive detection of liver fibrosis: Is superparamagnetic iron oxide particle-enhanced MR imaging a contributive technique? Eur Radiol 2003, 13:467-474.
155. Numminen K, Tervahartiala P, Halavaara J, Isoniemi H, Hockerstedt K: Noninvasive diagnosis of liver cirrhosis: magnetic resonance imaging presents special features. Scand J Gastroenterol 2005, 40:76-82.
156. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB: Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology 2006, 239:425-437.
157. Taura T, Nakamura K, Takashima S, Kaminou T, Yamada R, Shuto T, Wakasa K: Heterogeneity of hepatic parenchymal enhancement on computed tomography during arterial portography: quantitative analysis of correlation with severity of hepatic fibrosis. Hepatol Res 2001, 20:182-192.
158. Materne R, Annet L, Dechambre S, Sempoux C, Smith AM, Corot C, Horsmans Y, Van Beers BE: Dynamic computed tomography with low- and high-molecular-mass contrast agents to assess microvascular permeability modifications in a model of liver fibrosis. Clin Sci (Lond) 2002, 103:213-216.
159. Wang S, Fu D, Xu M, Hu D: Advanced fuzzy cellular neural network: application to CT liver images. Artif Intell Med 2007, 39:65-77. (Pubitemid 44894843)
160. Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Ledinghen V: Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005, 128:343-350. (Pubitemid 40439195)
161. Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, Martinot M, Bedossa P, Valla D, Vidaud M, Marcellin P: Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005, 129:2064-2075. (Pubitemid 41772981)
162. Smith MW, Walters KA, Korth MJ, Fitzgibbon M, Proll S, Thompson JC, Yeh MM, Shuhart MC, Furlong JC, Cox PP, et al: Gene expression patterns that correlate with hepatitis C and early progression to fibrosis in liver transplant recipients. Gastroenterology 2006, 130:179-187. (Pubitemid 43049848)
163. Huang H, Shiffman ML, Cheung RC, Layden TJ, Friedman S, Abar OT, Yee L, Chokkalingam AP, Schrodi SJ, Chan J, et al: Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006, 130:1679-1687. (Pubitemid 43668836)
164. Machida K, Cheng KT, Sung VM, Levine AM, Foung S, Lai MM: Hepatitis C virus induces toll-like receptor 4 expression, leading to enhanced production of beta interferon and interleukin-6. J Virol 2006, 80:866-874. (Pubitemid 43062898)
165. Huang H, Shiffman ML, Friedman S, Venkatesh R, Bzowej N, Abar OT, Rowland CM, Catanese JJ, Leong DU, Sninsky JJ, et al: A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007, 46:297-306. (Pubitemid 47344763)
166. Zeremski M, Petrovic LM, Chiriboga L, Brown QB, Yee HT, Kinkhabwala M, Jacobson IM, Dimova R, Markatou M, Talal AH: Intrahepatic levels of CXCR3-associated chemokines correlate with liver inflammation and fibrosis in chronic hepatitis C. Hepatology 2008, 48:1440-1450.
167. Zeremski M, Dimova R, Brown Q, Jacobson IM, Markatou M, Talal AH: Peripheral CXCR3-associated chemokines as biomarkers of fibrosis in chronic hepatitis C virus infection. J Infect Dis 2009, 200:1774-1780.
168. Kovalenko E, Tacke F, Gressner OA, Zimmermann HW, Lahme B, Janetzko A, Wiederholt T, Berg T, Muller T, Trautwein C, et al: Validation of connective tissue growth factor (CTGF/CCN2) and its gene polymorphisms as noninvasive biomarkers for the assessment of liver fibrosis. J Viral Hepat 2009, 16:612-620.
169. Sharma A, Chakraborti A, Das A, Dhiman RK, Chawla Y: Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 2009, 128:e514-522.
170. Caillot F, Hiron M, Goria O, Gueudin M, Francois A, Scotte M, Daveau M, Salier JP: Novel serum markers of fibrosis progression for the follow-up of hepatitis C virus-infected patients. Am J Pathol 2009, 175:46-53.
171. Gutierrez-Reyes G, Gutierrez-Ruiz MC, Kershenobich D: Liver fibrosis and chronic viral hepatitis. Arch Med Res 2007, 38:644-651. (Pubitemid 47001568)
172. Desmond PV, Patwardhan RV, Johnson RF, Schenker S: Impaired elimination of caffeine in cirrhosis. Dig Dis Sci 1980, 25:193-197. (Pubitemid 10107909)
173. Park GJ, Katelaris PH, Jones DB, Seow F, Le Couteur DG, Ngu MC: Validity of the 13C-caffeine breath test as a noninvasive, quantitative test of liver function. Hepatology 2003, 38:1227-1236. (Pubitemid 37314831)
174. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Ling M, Albrecht JK: Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965. (Pubitemid 32913521)
175. Kumar D, Farrell GC, Fung C, George J: Hepatitis C virus genotype 3 is cytopathic to hepatocytes: Reversal of hepatic steatosis after sustained therapeutic response. Hepatology 2002, 36:1266-1272. (Pubitemid 35253445)
176. Abe S, Tabaru A, Ono M, Tai M, Narita R, Moriyama A, Otsuki M: High-dose interferon-alpha therapy lowers the levels of serum fibrogenesis markers over 5 years in chronic hepatitis C. Hepatol Res 2003, 25:22-31. (Pubitemid 36367259)
177. Derbala MF, Al Kaabi SR, El Dweik NZ, Pasic F, Butt MT, Yakoob R, Al-Marri A, Amer AM, Morad N, Bener A: Treatment of hepatitis C virus genotype 4 with peginterferon alfa-2a: impact of bilharziasis and fibrosis stage. World J Gastroenterol 2006, 12:5692-5698. (Pubitemid 44594046)
178. Takemoto R, Nakamuta M, Aoyagi Y, Fujino T, Yasutake K, Koga K, Yoshimoto T, Miyahara T, Fukuizumi K, Wada Y, et al: Validity of FibroScan values for predicting hepatic fibrosis stage in patients with chronic HCV infection. J Dig Dis 2009, 10:145-148.
179. Vergniol J, Foucher J, Castera L, Bernard PH, Tournan R, Terrebonne E, Chanteloup E, Merrouche W, Couzigou P, de Ledinghen V: Changes of non-invasive markers and FibroScan values during HCV treatment. J Viral Hepat 2009, 16:132-140.
180. Halfon P, Carrat F, Bedossa P, Lambert J, Penaranda G, Perronne C, Pol S, Cacoub P: Effect of antiviral treatment on serum markers of liver fibrosis in HIV-hepatitis C virus-coinfected patients: the Fibrovic 2 Study - ANRS HC02. Antivir Ther 2009, 14:211-219.
181. Patel K, Benhamou Y, Yoshida EM, Kaita KD, Zeuzem S, Torbenson M, Pulkstenis E, Subramanian GM, McHutchison JG: An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009, 16:178-186.